

Hermann Einsele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6070945/publications.pdf>

Version: 2024-02-01

134
papers

14,546
citations

36203

51
h-index

20900

115
g-index

152
all docs

152
docs citations

152
times ranked

13844
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. <i>Journal of Nuclear Medicine</i> , 2022, 63, 96-99.	2.8	13
2	Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. <i>Leukemia</i> , 2022, 36, 790-800.	3.3	22
3	Salvage therapy with Daratumumab (Dara-CD19) in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2022, 40, 202-211.	0.8	9
4	Junctional adhesion molecule C expression specifies a CD138 ^{low} /neg multiple myeloma cell population in mice and humans. <i>Blood Advances</i> , 2022, 6, 2195-2206.	2.5	9
5	A Clinical Case of COVID-19-Associated Pulmonary Aspergillosis (CAPA), Illustrating the Challenges in Diagnosis (Despite Overwhelming Mycological Evidence). <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 81.	1.5	5
6	Molecular Profiling Reveals Characteristic and Decisive Signatures in Patients after Allogeneic Stem Cell Transplantation Suffering from Invasive Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1041-1053.	1.5	5
7	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
8	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 817-823.	1.3	4
9	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
10	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
11	Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 874-880.	1.3	3
12	Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 515-522.	1.2	7
13	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	1.7	46
14	Variant signaling topology at the cancer cell-T-cell interface induced by a two-component T-cell engager. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1568-1570.	4.8	3
15	COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan. <i>Annals of Hematology</i> , 2021, 100, 843-846.	0.8	1
16	Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 205-212.	1.2	11
17	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
18	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. <i>Annals of Hematology</i> , 2021, 100, 1537-1546.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. <i>Nature Medicine</i> , 2021, 27, 616-619.	15.2	140
20	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	3.3	40
21	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
22	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
23	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S433-S434.	0.6	1
24	Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 51.	2.8	3
25	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. <i>Cancers</i> , 2021, 13, 1322.	1.7	6
26	Diagnostic Performance of (1 β 3)- β -D-Glucan Alone and in Combination with Aspergillus PCR and Galactomannan in Serum of Pediatric Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 238.	1.5	6
27	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
28	CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. <i>Gene Therapy</i> , 2021, 28, 560-571.	2.3	70
29	Development of a Simple and Robust Whole Blood Assay with Dual Co-Stimulation to Quantify the Release of T-Cellular Signature Cytokines in Response to Aspergillus fumigatus Antigens. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 462.	1.5	9
30	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. <i>Communications Biology</i> , 2021, 4, 799.	2.0	16
31	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. <i>Blood</i> , 2021, 137, 3145-3148.	0.6	70
32	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1830-1842.	0.6	40
33	Chronic Occupational Mold Exposure Drives Expansion of Aspergillus-Reactive Type 1 and Type 2 T-Helper Cell Responses. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 698.	1.5	6
34	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2
35	Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. <i>Blood Advances</i> , 2021, 5, 3794-3798.	2.5	30
36	Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. <i>Communications Biology</i> , 2021, 4, 44.	2.0	7

#	ARTICLE	IF	CITATIONS
37	T-Cell Immune Surveillance in Allogenic Stem Cell Transplant Recipients: Are Whole Blood-Based Assays Ready to Challenge ELISPOT?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa547.	0.4	1
38	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
39	Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6157.	1.7	12
40	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 352-355.	1.1	6
41	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
42	Excretion of <i>Ascaris lumbricoides</i> following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole. <i>Transplant Infectious Disease</i> , 2020, 22, e13224.	0.7	3
43	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
44	<i>CIC</i> Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. <i>Oncologist</i> , 2020, 25, 112-118.	1.9	39
45	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1243.	1.3	63
46	What is the future of immunotherapy in multiple myeloma?. <i>Blood</i> , 2020, 136, 2491-2497.	0.6	22
47	Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia. <i>Mycoses</i> , 2020, 63, 1101-1106.	1.8	6
48	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	2.8	90
49	Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. <i>Current Opinion in Oncology</i> , 2020, 32, 418-426.	1.1	14
50	Three-Dimensional Light Sheet Fluorescence Microscopy of Lungs To Dissect Local Host Immune- <i>Aspergillus fumigatus</i> Interactions. <i>MBio</i> , 2020, 11, .	1.8	49
51	The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
52	The screening of blood by <i>Aspergillus</i> PCR and galactomannan ELISA precedes BAL detection in patients with proven and probable IA. <i>Medical Mycology</i> , 2020, 58, 856-858.	0.3	4
53	Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. <i>Cancers</i> , 2020, 12, 1035.	1.7	28
54	Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+ <i>Aspergillus fumigatus</i> specific T-cell quantification. <i>Medical Microbiology and Immunology</i> , 2020, 209, 579-592.	2.6	3

#	ARTICLE	IF	CITATIONS
55	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 762.	2.2	57
56	Inhibition of TGF- β 2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. , 2020, 8, e000676.		75
57	BATF3 programs CD8+ T cell memory. <i>Nature Immunology</i> , 2020, 21, 1397-1407.	7.0	80
58	Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
59	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 60-64.	2.8	62
60	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
61	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , 2019, 33, 447-456.	3.3	93
62	Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. <i>Nature Communications</i> , 2019, 10, 3137.	5.8	120
63	The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	326
64	Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane. <i>British Journal of Haematology</i> , 2019, 187, 386-395.	1.2	8
65	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. <i>European Journal of Haematology</i> , 2019, 103, 255-267.	1.1	6
66	Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells. <i>Medical Mycology</i> , 2019, 58, 187-196.	0.3	7
67	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
68	On-target restoration of a split T cell-engaging antibody for precision immunotherapy. <i>Nature Communications</i> , 2019, 10, 5387.	5.8	38
69	Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation. <i>Scientific Reports</i> , 2019, 9, 17231.	1.6	5
70	A highly soluble Sleeping Beauty transposase improves control of gene insertion. <i>Nature Biotechnology</i> , 2019, 37, 1502-1512.	9.4	63
71	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. <i>Journal of Immunotherapy</i> , 2019, 42, 180-188.	1.2	17
72	Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 561-571.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. <i>British Journal of Haematology</i> , 2019, 184, 440-443.	1.2	25
74	ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. <i>JCI Insight</i> , 2019, 4, .	2.3	139
75	Susceptibility of <i>A. fumigatus</i> -specific T-cell assays to pre-analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes. <i>Mycoses</i> , 2018, 61, 549-560.	1.8	13
76	CAR T-cells targeting FLT3 have potent activity against FLT3 ^{ITD} + AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , 2018, 32, 1168-1179.	3.3	133
77	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. <i>Expert Review of Hematology</i> , 2018, 11, 219-237.	1.0	28
78	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	28
79	Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. <i>Haematologica</i> , 2018, 103, e126-e129.	1.7	28
80	Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure. <i>International Journal of Medical Microbiology</i> , 2018, 308, 1018-1026.	1.5	13
81	Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2018, 1792, 117-128.	0.4	6
82	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
83	CAR T cells targeting α _v β ₃ integrin are effective against advanced cancer in preclinical models. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e11.	0.6	45
84	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	0.6	335
85	Human primary myeloid dendritic cells interact with the opportunistic fungal pathogen <i>Aspergillus fumigatus</i> via the C-type lectin receptor Dectin-1. <i>Medical Mycology</i> , 2017, 55, myw105.	0.3	21
86	Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. <i>Blood</i> , 2017, 129, 3386-3388.	0.6	79
87	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
88	Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. <i>British Journal of Haematology</i> , 2017, 179, 586-597.	1.2	30
89	SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. <i>Blood</i> , 2017, 130, 2838-2847.	0.6	164
90	Intra- and inter-individual variability of <i>Aspergillus fumigatus</i> reactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment. <i>Mycoses</i> , 2017, 60, 668-675.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796
92	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the ^{PANORAMA} 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	1.2	16
93	Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients. <i>Journal of Clinical Microbiology</i> , 2017, 55, 101-109.	1.8	21
94	¹¹C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. <i>Theranostics</i> , 2017, 7, 2956-2964.	4.6	63
95	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. <i>Theranostics</i> , 2017, 7, 1589-1597.	4.6	102
96	Common Genetic Polymorphisms within NF κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	1.5	13
97	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
98	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	0.6	121
99	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. <i>Journal of Experimental Medicine</i> , 2016, 213, 1881-1900.	4.2	143
100	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1988-1996.	2.0	40
101	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1104-1111.	0.8	359
102	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	2.8	201
103	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
104	Human Invariant Natural Killer T cells possess immune-modulating functions during <i>Aspergillus</i> infection. <i>Medical Mycology</i> , 2016, 54, 169-176.	0.3	8
105	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 38762-38774.	0.8	3
106	<i>In vivo</i> molecular imaging of chemokine receptor ^{CXCR} 4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	3.3	180
107	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
108	Effect of ATG ϵ F on B ϵ cell reconstitution after hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 95, 514-523.	1.1	14

#	ARTICLE	IF	CITATIONS
109	Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 3365-3369.	0.6	2
110	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	5.1	347
111	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	1.1	10
112	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	1.7	185
113	The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 1207-1214.	0.8	29
114	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
115	Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. <i>Blood</i> , 2014, 124, 628-637.	0.6	103
116	Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. <i>British Journal of Haematology</i> , 2013, 161, 517-524.	1.2	61
117	Multicenter Comparison of Serum and Whole-Blood Specimens for Detection of Aspergillus DNA in High-Risk Hematological Patients. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1445-1450.	1.8	74
118	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
119	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.2	40
120	Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. <i>Annals of Hematology</i> , 2012, 91, 1031-1037.	0.8	82
121	Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e52398.	1.1	24
122	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
123	Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2009, 48, 1392-1401.	2.9	110
124	Interaction analyses of human monocytes co-cultured with different forms of <i>Aspergillus fumigatus</i> . <i>Journal of Medical Microbiology</i> , 2009, 58, 49-58.	0.7	50
125	Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1143-1238.	2.0	1,505
126	Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control. <i>Blood</i> , 2009, 114, 1123-1123.	0.6	17

#	ARTICLE	IF	CITATIONS
127	Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International Journal of Hematology, 2008, 88, 508-515.	0.7	94
128	Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of "Deutsche Studiengruppe Multiples Myelom". Blood, 2008, 112, 2782-2782.	0.6	1
129	Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.. Blood, 2008, 112, 3274-3274.	0.6	7
130	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 2007, 138, 330-337.	1.2	156
131	Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program.. Blood, 2007, 110, 4834-4834.	0.6	0
132	Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood, 2006, 107, 3002-3008.	0.6	104
133	Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation. Drugs, 1998, 55, 59-72.	4.9	46
134	A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity. Frontiers in Immunology, 0, 13, .	2.2	10